This firm currently holds 248.36
M in liabilities with Debt to Equity (D/E) ratio of 0.67, which is about average as compared to similar companies.
What is the right price you would pay to acquire a share of TherapeuticsMD? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the
future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our
stock advisor page.
What is happening with TherapeuticsMD this year
Annual and quarterly reports issued by TherapeuticsMD are formal
financial statements that are published yearly and quarterly and sent to TherapeuticsMD stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the
Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as TherapeuticsMD often view their annual report as an effective marketing tool to disseminate their perspective on company
future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.
TherapeuticsMD Gross Profit
TherapeuticsMD Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing TherapeuticsMD previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show TherapeuticsMD Gross Profit growth over the last 10 years. Please check TherapeuticsMD's
gross profit and other
fundamental indicators for more details.
Breaking it down
Analysts have increased confidence in Therapeuticsmd as compared to a month ago. The current consensus of 4 analysts is Strong Buy.
Is Therapeuticsmd a risky opportunity?
Let's check the volatility. Therapeuticsmd is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Therapeuticsmd (NASDAQ:TXMD) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. purchasing a share of a Therapeuticsmd stock makes you a part-owner of that company.
Therapeuticsmd Current Consensus
Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Therapeuticsmd. The Therapeuticsmd consensus assessment is calculated by taking the average estimates from all of the analysts covering Therapeuticsmd
| Strong Buy | 4 | 100.0 |
| Buy | 0 | 0.0 |
| Hold | 0 | 0.0 |
| Sell | 0 | 0.0 |
| Strong Sell | 0 | 0.0 |
Therapeuticsmd latest price dip can leaving shareholders with little time to react
Therapeuticsmd latest potential upside ascents over 7.1. Therapeuticsmd exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Therapeuticsmd individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Therapeuticsmd future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Therapeuticsmd's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Therapeuticsmd's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Our Bottom Line On Therapeuticsmd
Although some firms within the drug manufacturers—specialty & generic industry are still a little expensive, even after the recent corrections, Therapeuticsmd may offer a potential longer-term growth to shareholders. The inconsistency in the assessment between current Therapeuticsmd valuation and our trade advice on Therapeuticsmd is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Therapeuticsmd.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Rifka Kats is a Member of Macroaxis Editorial Board. Rifka writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Rifka Kats do not own shares of TherapeuticsMD. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
